Antimicrobial activities of levofloxacin, clarithromycin, and KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium complex replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines

International Journal of Antimicrobial Agents

Volumn 16, Issue 1, 2000, Pages 25-29

  Sato, Katsumasa ^a   Tomioka, Haruaki ^a   Akaki, Tatsuya ^a   Kawahara, Shin ^b  

^a SHIMANE UNIVERSITY   (Japan)

^b National Hospital Organization   (Japan)

Author keywords

Clarithromycin; KRM 1648; Levofloxacin; Mycobacterium avium complex; Mycobacterium tuberculosis; Type II alveolar epithelial cells

Indexed keywords

CLARITHROMYCIN; LEVOFLOXACIN; RIFALAZIL; RIFAMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; INCUBATION TIME; INTERNALIZATION; LUNG ALVEOLUS CELL TYPE 2; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM INTRACELLULARE AVIUM; MYCOBACTERIUM TUBERCULOSIS; PHAGOCYTE; PRIORITY JOURNAL;

EID: 0033843029     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(00)00163-1     Document Type: Article

References (21)

1. Raviglione M.C., Snider D.E. Jr, Kochi A. Global epidemiology of tuberculosis.morbidity and mortality of a worldwide epidemic. J. Am. Med. Assoc. 273:1995;220-226.
2. Inderlied C.D., Kemper C.A., Bermudez L.E. The Mycobacterium avium complex. Clin. Microbiol. Rev. 6:1993;266-310.
3. Yew W.W., Chau C.H. Drug-resistant tuberculosis in the 1990s. Eur. Respir. J. 8:1995;1184-1192.
4. Hart C.A., Beeching N.J., Duerden B.I. Tuberculosis into the next century. J. Med. Microbiol. 4:1996;1-34.
5. Falkinham J.O. Epidemiology of infection by nontuberculous mycobacteria. Clin. Microbiol. Rev. 9:1996;177-215.
6. Bermudez L.E., Goodman J. Mycobacterium tuberculosis invades and replicates within type II alveolar cells. Infect. Immun. 64:1996;1400-1406.
7. McDonough K.A., Kress Y. Cytotoxicity for lung epithelial cells is a virulence-associated phenotype of Mycobacterium tuberculosis. Infect. Immun. 63:1995;4802-4811.
8. Mehta P.K., King C.H., White E.H., Murtagh J.J. Jr, Quinn F.D. Comparison of in vitro models for the study of Mycobacterium tuberculosis invasion and intracellular replication. Infect. Immun. 64:1996;2673-2677.
9. Ji B., Lounis N., Truffot-Pernot C., Grosset J. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 39:1995;1341-1344.
10. Saito H., Sato K., Tomioka H., Dekio S. In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR-3355). Tuberc. Lung Dis. 76:1995;377-380.
11. Dautzenberg B. Clinical trials in Mycobacterium avium therapy: lessons to take home. Res. Microbiol. 145:1994;197-206.
12. Heifets L.B. Clarithromycin against Mycobacterium avium complex infections. Tuberc. Lung Dis. 77:1996;19-26.
13. Sato K., Akaki T., Tomioka H. Antimicrobial activities of benzoxazinorifamycin KRM-1648, clarithromycin, and levofloxacin against intracellular Mycobacterium avium complex phagocytosed by murine preitoneal macrophages. J. Antimicrob. Chemother. 41:1998;77-83.
14. Tomioka H., Sato K., Hidaka H., Saito H. In vitro and in vivo antimycobacterial activities of KRM-1648, a new benzoxazinorifamycin. Pandalai S.G. Recent Research Developments in Antimicrobial Agents and Chemotherapy. 2:1997;Research Signpost, Trivandrum.
15. Sato K., Tomioka H. Antimicrobial activities of benzoxazinorifamycin (KRM-1648) and clarithromycin against Mycobacterium avium-intracellulare complex within murine peritoneal macrophages, human macrophage-like cells and human alveolar epithelial cells. J. Antimicrob. Chemother. 43:1999;351-357.
16. Ziegler-Heitbrock H.W.L., Thiel E., Futterer A., Herzog V., Wirtz A. Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes. Int. J. Cancer. 41:1988;456-461.
17. Shattock R.J., Friedland J.S., Griffin G.E. Phagocytosis of Mycobacterium tuberculosis modulates human immunodeficiency virus replication in human monocytic cells. J. Gen. Virol. 75:1994;849-856.
18. Wright E.L., Quenelle D.C., Suling W.J., Barrow W.W. Use of Mono Mac 6 human monocytic cell line and J774 murine macrophage cell line in parallel antimycobacterial drug studies. Antimicrob. Agents Chemother. 40:1996;2206-2208.
19. Suwa T., Urano H., Kodama T., Kanamura M. Metabolic fate of TE-031 (A-56268). (VIII) Absorption and excretion in humans (bioassay). Chemotherapy. 36:1988;921-932.
20. Yajko D.M., Nassos P.S., Hadley W.K. Broth microdilution testing of susceptibilities to 30 antimicrobial agents of Mycobacterium avium from patients with acquired immune deficiency symdrome. Antimicrob. Agents Chemother. 31:1987;1579-1584.
21. Kanai K., Kondo E., Yasuda T. Ultrastructural changes in the alveolar epithelium in response to mycobacterial infection. Jpn. J. Med. Sci. Biol. 32:1979;315-325.